Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” ...

Alexion has said it can ramp up production if the drug works in trials but what it has not mentioned is its cost: Ultomiris is hugely expensive when used in rare diseases, costing several thousand ...

Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a ...

It’s a rare disease niche that is already exploited by the Alexion, which has Soliris and ... and immunology franchises with late and early-state pipeline projects".

Alexion studies rare diseases, including two in the rare neurology space: generalized myasthenia gravis (gMG), which causes muscle weakness, and neuromyelitis optica spectrum disorder (NMOSD ...

Cardiac surgery-associated acute kidney injury (CSA-AKI) occurs in ≥50% of patients with chronic kidney disease (CKD) undergoing cardiac surgery with cardiopulmonary bypass (CPB) 2. At Alexion ...